Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.

@article{Marschner2010PhaseIS,
  title={Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.},
  author={Norbert Marschner and Dominik Ruettinger and Gerhard Zugmaier and Gyula Nemere and Jan Lehmann and Peter Obrist and Patrick A. Baeuerle and Andreas M. Wolf and Margit Schmidt and Per Anders Abrahamsson and Carsten Reinhardt and Axel Heidenreich},
  journal={Urologia internationalis},
  year={2010},
  volume={85 4},
  pages={386-95}
}
BACKGROUND Rising serum levels of prostate-specific antigen (PSA) after radical prostatectomy are indicative of recurrent prostate cancer. This double-blind, placebo-controlled phase II study evaluated the anti-tumour activity of the anti-epithelial cell adhesion molecule (EpCAM) antibody adecatumumab in delaying biochemical disease progression. PATIENTS AND METHODS Prostate cancer patients with increasing serum PSA levels following radical prostatectomy were randomized to low- (2 mg/kg) or… CONTINUE READING
11 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…